OncoMed Pharmaceuticals, Inc.
     
 
 

Press Releases

All Releases
View Summary OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018
Feb 22, 2018
PDF 11.6 KB Add to Briefcase
View Summary OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned
Jan 4, 2018
PDF 14.8 KB Add to Briefcase
View Summary OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program
Jan 4, 2018
PDF 18.8 KB Add to Briefcase
View Summary OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities
Nov 27, 2017
PDF 12.8 KB Add to Briefcase
View Summary OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
Nov 2, 2017
PDF 26.8 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017
Oct 24, 2017
PDF 12.1 KB Add to Briefcase
View Summary OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence
Sep 19, 2017
PDF 12.8 KB Add to Briefcase
View Summary OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
Sep 13, 2017
PDF 15.6 KB Add to Briefcase
View Summary OncoMed Announces Second Quarter 2017 Financial Results
Aug 2, 2017
PDF 26.9 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Report Second Quarter Financial Results on August 2nd, 2017
Jul 26, 2017
PDF 11.8 KB Add to Briefcase
View Summary OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
May 8, 2017
PDF 26.0 KB Add to Briefcase
View Summary OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial
May 4, 2017
PDF 16.6 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017
May 3, 2017
PDF 11.7 KB Add to Briefcase
View Summary OncoMed Announces Workforce Reduction
Apr 24, 2017
PDF 17.4 KB Add to Briefcase
View Summary OncoMed's Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Apr 17, 2017
PDF 17.8 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
Apr 10, 2017
PDF 14.5 KB Add to Briefcase
View Summary OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint
Apr 10, 2017
PDF 22.3 KB Add to Briefcase
View Summary OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017
Apr 5, 2017
PDF 19.4 KB Add to Briefcase
View Summary OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
Apr 3, 2017
PDF 19.4 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
Mar 8, 2017
PDF 34.0 KB Add to Briefcase
Showing 1-20 of 215 Page: 1 2 3 4 5 ... 11  Next 20
Add to Briefcase = add release to Briefcase
Stock Quote (NASDAQ: OMED)
Price:
2.16
Change:
0.00
Day High:
2.20
Day Low:
2.05
Volume:
122,141
4:00 PM ET on Feb 23, 2018
Delayed at least 20 minutes.
Provided by eSignal.
Search Investor Relations